Showing 3 posts of 3 posts found.


Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis

July 15, 2020
Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis

Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …


Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression

March 21, 2019
Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs

The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …


Top Ten most popular articles on Pharmafile.com this week

October 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Jannsen, NHS, Novartis, Novo Nordisk, dementia, top 10

As September came to a close and October began the UK was hit hard in the headlines after American firm …

Latest content